Average Ratings 0 Ratings
Average Ratings 0 Ratings
Description
BrainSightAI is an innovative health technology firm that harnesses the power of artificial intelligence and machine learning to transform the field of brain mapping through AI-driven connectomics, allowing for the creation of customized brain maps. The VoxelBox product line employs these AI techniques to produce individualized brain maps tailored to each patient's needs. These advanced tools are specifically designed to facilitate pre-surgical preparation and enhance patient outcomes for those suffering from brain tumors and various neurological issues. Collaborating with top hospitals across the country, BrainSightAI is engaged in clinical trials that explore a range of brain-related ailments such as Alzheimer's disease, brain tumors, psychiatric disorders, Parkinson's disease, and stroke. Committed to pushing the boundaries of brain science, our overarching goal is to improve quality of life by offering state-of-the-art resources that deepen our understanding of the human brain and its complexities. By continually refining our technology and methodologies, we aspire to make significant contributions to the medical community and the lives of patients.
Description
Introducing a versatile API designed to seamlessly integrate with your diabetes management system, offering tailored therapeutic education and enhanced insights into blood glucose level fluctuations. This solution enables real-time risk predictions, fostering greater personalization and improved system regulation, while adeptly managing complex living scenarios characterized by rapid glucose variations. With advancements in telemedicine and retrospective analysis, patients receive robust decision-support tools. Currently, Hillo is developing the next iterations of its AI technology, which includes a therapeutic recommendation system aimed at preventing hypoglycemia and hyperglycemia, anticipated to achieve CE mark class IIB by 2020. Additionally, a new generation of the artificial pancreas is projected for release in 2021, addressing key limitations of existing systems through ultra-personalization driven by machine learning. This innovative approach marks the introduction of the first self-learning artificial intelligence capable of predicting blood glucose levels, aiming to secure a CE mark as a medical device, thereby transforming diabetes management for users. In essence, Hillo's advancements could significantly enhance the quality of life for individuals managing diabetes.
API Access
Has API
No
API Access
Has API
Yes
Integrations
No details available.
Integrations
No details available.
Pricing Details
No price information available.
Free Trial
No
Free Version
No
Pricing Details
No price information available.
Free Trial
Yes
Free Version
No
Deployment
Web-Based
Yes
On-Premises
No
iPhone App
No
iPad App
No
Android App
No
Windows
No
Mac
No
Linux
No
Chromebook
No
Deployment
Web-Based
Yes
On-Premises
No
iPhone App
No
iPad App
No
Android App
No
Windows
No
Mac
No
Linux
No
Chromebook
No
Customer Support
Business Hours
Yes
Live Rep (24/7)
No
Online Support
Yes
Customer Support
Business Hours
No
Live Rep (24/7)
No
Online Support
Yes
Types of Training
Training Docs
Yes
Webinars
No
Live Training (Online)
No
In Person
Yes
Types of Training
Training Docs
Yes
Webinars
No
Live Training (Online)
No
In Person
Yes
Vendor Details
Company Name
BrainSightAI
Country
India
Website
www.brainsightai.com
Vendor Details
Company Name
Hillo
Country
France
Website
www.hillo.ai/
Product Features
Medical Imaging
Automated Routing
No
Comparison View
No
Compliance Management
No
Data Import / Export
No
Diagnostic Reporting
No
Image Analytics
No
Treatment Planning
No
Workflow Management
No